JP2022533705A5 - - Google Patents
Info
- Publication number
- JP2022533705A5 JP2022533705A5 JP2021569042A JP2021569042A JP2022533705A5 JP 2022533705 A5 JP2022533705 A5 JP 2022533705A5 JP 2021569042 A JP2021569042 A JP 2021569042A JP 2021569042 A JP2021569042 A JP 2021569042A JP 2022533705 A5 JP2022533705 A5 JP 2022533705A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- complement
- neuropathy
- antigen
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024220534A JP2025038109A (ja) | 2019-05-21 | 2024-12-17 | 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト |
| JP2024221343A JP2025041724A (ja) | 2019-05-21 | 2024-12-18 | 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1907153.9A GB2584105B (en) | 2019-05-21 | 2019-05-21 | Methods of treating neuropathy |
| GB1907153.9 | 2019-05-21 | ||
| PCT/EP2020/064234 WO2020234432A1 (en) | 2019-05-21 | 2020-05-21 | Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024220534A Division JP2025038109A (ja) | 2019-05-21 | 2024-12-17 | 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト |
| JP2024221343A Division JP2025041724A (ja) | 2019-05-21 | 2024-12-18 | 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022533705A JP2022533705A (ja) | 2022-07-25 |
| JP2022533705A5 true JP2022533705A5 (cg-RX-API-DMAC7.html) | 2023-05-31 |
| JP7607590B2 JP7607590B2 (ja) | 2024-12-27 |
Family
ID=67385155
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021569042A Active JP7607590B2 (ja) | 2019-05-21 | 2020-05-21 | 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト |
| JP2024220534A Pending JP2025038109A (ja) | 2019-05-21 | 2024-12-17 | 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト |
| JP2024221343A Pending JP2025041724A (ja) | 2019-05-21 | 2024-12-18 | 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024220534A Pending JP2025038109A (ja) | 2019-05-21 | 2024-12-17 | 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト |
| JP2024221343A Pending JP2025041724A (ja) | 2019-05-21 | 2024-12-18 | 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト |
Country Status (21)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3893924T3 (pl) * | 2018-12-13 | 2025-01-13 | argenx BV | Przeciwciała przeciwko ludzkiemu czynnikowi c2b dopełniacza i sposoby zastosowania |
| CN117597353A (zh) * | 2021-03-18 | 2024-02-23 | 艾菲洛之克公司 | 抗因子c3的sac7d变体及其治疗补体介导疾患的医疗用途 |
| EP4308591A4 (en) * | 2021-03-18 | 2025-04-02 | Affilogic | POLYPEPTIDES FOR COMPLEMENT INHIBITION |
| EP4059949A1 (en) * | 2021-03-18 | 2022-09-21 | Affilogic | Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders |
| US20240166692A1 (en) * | 2021-03-18 | 2024-05-23 | Affilogic | Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders |
| MX2024008273A (es) * | 2021-12-30 | 2024-07-19 | Annexon Inc | Composiciones y metodos para el tratamiento de la enfermedad de huntington. |
| MA71448A (fr) * | 2022-07-14 | 2025-04-30 | argenx BV | Régimes posologiques pour le traitement d'une neuropathie motrice multifocale (nmm) |
| EP4676952A2 (en) * | 2023-03-07 | 2026-01-14 | The Cleveland Clinic Foundation | Human complement component 2 binding molecules |
| WO2025146509A1 (en) * | 2024-01-05 | 2025-07-10 | argenx BV | Methods of treating multifocal motor neuropathy (mmn) |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US8501705B2 (en) * | 2003-09-11 | 2013-08-06 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions |
| WO2008030505A2 (en) * | 2006-09-05 | 2008-03-13 | Alexion Pharmaceuticals, Inc. | Methods and compositions for the treatment of antibody mediated neuropathies |
| GB0617734D0 (en) * | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
| LT3028716T (lt) * | 2006-10-10 | 2020-12-10 | Regenesance B.V. | Komplemento slopinimas nervų regeneracijos pagerinimui |
| JP6223659B2 (ja) * | 2008-11-10 | 2017-11-01 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 補体関連障害を処置するための方法および組成物 |
| WO2010056399A1 (en) * | 2008-11-17 | 2010-05-20 | Incode Biopharmaceutics, Inc. | Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors |
| PL2753636T3 (pl) * | 2011-09-07 | 2020-05-18 | The Trustees Of The University Of Pennsylvania | Analogi kompstatyny o ulepszonych właściwościach farmakokinetycznych |
| CN102949719A (zh) * | 2012-04-28 | 2013-03-06 | 上海市徐汇区中心医院 | 静脉注射免疫球蛋白抑制霍乱毒素和半乳糖凝集素-1结合到神经节苷脂gm1 |
| WO2014096958A1 (en) * | 2012-11-02 | 2014-06-26 | Academisch Medisch Centrum | Inosine monophosphate and salts thereof for use in the treatment of complement-related disorders |
| EP2997045A4 (en) * | 2013-05-15 | 2016-11-23 | Annexon Inc | ANTI-FACTOR C1S ANTIBODIES OF THE COMPLEMENT AND USES THEREOF |
| US9944717B2 (en) | 2013-05-23 | 2018-04-17 | Broteio Pharma B.V. | Binding molecules that bind human complement factor C2 and uses thereof |
| WO2015089368A2 (en) * | 2013-12-12 | 2015-06-18 | Alnylam Pharmaceuticals, Inc. | Complement component irna compositions and methods of use thereof |
| PL3215527T3 (pl) * | 2014-11-05 | 2025-04-28 | Annexon, Inc. | Humanizowane przeciwciała przeciwko czynnikowi dopełniacza C1Q i ich zastosowanie |
| CN108026134A (zh) * | 2015-09-16 | 2018-05-11 | 巴塞尔大学 | 结合抗糖鞘脂糖蛋白表位抗体的碳水化合物配体 |
| FI3380518T3 (fi) * | 2015-11-24 | 2026-05-29 | Annexon Inc | Antikomplementtitekijä-C1Q:n Fab-fragmentteja ja niiden käyttöjä |
| WO2017196960A1 (en) * | 2016-05-10 | 2017-11-16 | Annexon, Inc. | Anti-complement factor c4/c4b antibodies and uses thereof |
| SG11201907583TA (en) * | 2017-03-14 | 2019-09-27 | Bioverativ Usa Inc | Methods for treating complement-mediated diseases and disorders |
| CA3078971A1 (en) * | 2017-11-01 | 2019-05-09 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof |
| PL3893924T3 (pl) * | 2018-12-13 | 2025-01-13 | argenx BV | Przeciwciała przeciwko ludzkiemu czynnikowi c2b dopełniacza i sposoby zastosowania |
-
2019
- 2019-05-21 GB GB1907153.9A patent/GB2584105B/en active Active
-
2020
- 2020-05-21 BR BR112021023198A patent/BR112021023198A2/pt unknown
- 2020-05-21 CA CA3138401A patent/CA3138401A1/en active Pending
- 2020-05-21 AU AU2020279543A patent/AU2020279543B2/en active Active
- 2020-05-21 HU HUE20729653A patent/HUE072743T2/hu unknown
- 2020-05-21 CN CN202080037596.6A patent/CN114269382B/zh active Active
- 2020-05-21 DK DK20729653.4T patent/DK3972643T3/da active
- 2020-05-21 MA MA71752A patent/MA71752A/fr unknown
- 2020-05-21 PL PL20729653.4T patent/PL3972643T3/pl unknown
- 2020-05-21 EA EA202193189A patent/EA202193189A1/ru unknown
- 2020-05-21 FI FIEP20729653.4T patent/FI3972643T3/fi active
- 2020-05-21 JP JP2021569042A patent/JP7607590B2/ja active Active
- 2020-05-21 EP EP25159620.1A patent/EP4570316A3/en active Pending
- 2020-05-21 PT PT207296534T patent/PT3972643T/pt unknown
- 2020-05-21 CN CN202410047987.6A patent/CN118021970A/zh active Pending
- 2020-05-21 MX MX2021014170A patent/MX2021014170A/es unknown
- 2020-05-21 EP EP20729653.4A patent/EP3972643B1/en active Active
- 2020-05-21 SG SG11202112232YA patent/SG11202112232YA/en unknown
- 2020-05-21 ES ES20729653T patent/ES3035736T3/es active Active
- 2020-05-21 KR KR1020217039139A patent/KR20220010505A/ko active Pending
- 2020-05-21 LT LTEPPCT/EP2020/064234T patent/LT3972643T/lt unknown
- 2020-05-21 WO PCT/EP2020/064234 patent/WO2020234432A1/en not_active Ceased
-
2021
- 2021-11-11 IL IL288010A patent/IL288010A/en unknown
- 2021-11-18 MX MX2025014486A patent/MX2025014486A/es unknown
-
2024
- 2024-12-17 JP JP2024220534A patent/JP2025038109A/ja active Pending
- 2024-12-18 JP JP2024221343A patent/JP2025041724A/ja active Pending
-
2026
- 2026-07-01 AU AU2026205212A patent/AU2026205212A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11167038B2 (en) | Methods for improving safety of blood-brain barrier transport | |
| JP7071349B2 (ja) | ピログルタメートアミロイド-βに対する抗体及びその使用 | |
| JP5695317B2 (ja) | 抗体媒介性ニューロパシーを処置するための方法および組成物 | |
| KR101999872B1 (ko) | 혈뇌 장벽 투과성의 조정에 있어서의 세마포린-4d 결합 분자의 용도 | |
| CN107074965B (zh) | 特异性结合微管相关蛋白tau的抗体和抗原结合片段 | |
| ES2756649T3 (es) | Anticuerpos contra tau y usos de los mismos | |
| JP2020007318A5 (cg-RX-API-DMAC7.html) | ||
| JP2021191267A5 (cg-RX-API-DMAC7.html) | ||
| FI3972643T3 (fi) | Komplementtijärjestelmän antagonisteja käytettäväksi paraproteinemisten neuropatioiden hoitomenetelmissä | |
| AU2011336716A1 (en) | Low affinity blood brain barrier receptor antibodies and uses therefor | |
| CN109562167A (zh) | 联合治疗 | |
| WO2021212049A2 (en) | Anti-sars-cov-2 monoclonal antibodies | |
| CN102037018A (zh) | 识别结合了抗原的抗体与没有结合抗原的抗体的结构变化的抗体及其获得方法 | |
| CN107001452A (zh) | 用于治疗癌症的抗ck8抗体 | |
| JP2023537078A5 (cg-RX-API-DMAC7.html) | ||
| CN114605532B (zh) | 抗β-淀粉样蛋白抗体及其用途 | |
| CN114594272B (zh) | 用于检测β-淀粉样蛋白的产品和方法 | |
| JP5683466B2 (ja) | 抗psk抗体 | |
| CN119546631A (zh) | 用于治疗支气管扩张的抗PcrV和Psl双特异性抗体 | |
| NZ781789B2 (en) | Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies | |
| CN114591429B (zh) | 结合β-淀粉样蛋白的抗体及其用途 | |
| HK40063067B (en) | Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies | |
| HK1191341B (en) | Low affinity blood brain barrier receptor antibodies and uses therefor | |
| HK1259793B (en) | Methods for improving safety of blood-brain barrier transport |